The human cardiac organoid (hCO) is three-dimensional tissue model that is similar to an in
vivo organ and has great potential on heart development biology, disease modeling, drug …

Cardiovascular disease (CVD) caused by anti-cancer drug-induced cardiotoxicity is now the
second leading cause of mortality among cancer survivors. It is necessary to establish …

Abstract Purpose of Review In this review article we describe the cardiovascular adverse
events associated with BRAF and MEK inhibitors as well as their pathophysiologic …

A mechanism exploration is an important part of toxicological studies. However, traditional
cell and animal models can no longer meet the current needs for in-depth studies of …

Aim With the advancement of anti-cancer medicine, cardiovascular toxicities due to cancer
therapies are common in oncology patients, resulting in increased mortality and economic …

ABSTRACT MAPK has been reported as a key oncogenic pathway for canine histiocytic
sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of …

Simple Summary Targeted therapies with BRAF-and MEK-inhibitors have significantly
improved outcomes for patients with metastatic melanoma, but they come with a risk of heart …

Heart failure and cancer remain two of the leading causes of morbidity and mortality and the
two disease entities are linked in a complex manner. Patients with cancer are at increased …

Background Cancer survivors (CS) comprise a particularly high-risk group for both de-novo
and recurrent malignancies after solid organ transplantation. Case presentation We report a …

Post-translational modifications (PTMs) are protein modifications that occur after protein
biosynthesis, playing a crucial role in regulating protein function. They are involved in the …